§ Legislative Act Essential Goods
Public Generic Drug Manufacturing
Current Status
Existing Law: Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 301 et seq.). Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Act). Medicare Modernization Act of 2003 (Part D). Defense Production Act (50 U.S.C. § 4501 et seq.).
Current Authority: FDA regulates drug safety and manufacturing. HHS administers Medicare drug benefits. Private manufacturers control 100% of domestic generic production. Strategic National Stockpile managed by ASPR with contracted private suppliers.
Existing Limitations: No federal authority to manufacture pharmaceuticals directly. No price controls on generic drugs post-patent. No mandatory domestic production requirements. No accountability mechanism for chronic shortage conditions. Strategic National Stockpile dependent on same private suppliers causing civilian shortages.
Problem
Specific Harm: 323 active drug shortages (Q1 2024) affecting 500,000+ patients per shortage¹. 1,961 unique products in shortage (2018-2023)¹. Median shortage duration 4.0 years for essential medicines¹. Price exploitation cases include EpiPen (+509%), Daraprim (+5,456%), insulin (+200%). 62% of shortages caused by manufacturing/quality failures at private facilities².
Who is Affected: Medicare beneficiaries paying 200-500% inflated prices. Hospitals rationing essential injectables. Emergency departments unable to stock critical medications. Cancer patients facing chemotherapy delays. Diabetic patients rationing insulin.
Gaps in Current Law: No federal manufacturing capacity for essential medicines. No price intervention authority for off-patent generics. No surge production capability for emergencies. No domestic API production requirements. FDA shortage authority limited to notification, not prevention.
Accountability Failures: FDA monitors shortages but cannot compel production. Private manufacturers face no penalties for exiting unprofitable markets. No independent body to adjudicate market failure determinations or pricing disputes. Strategic National Stockpile procurement decisions made without independent oversight of contractor selection.
Proposed Reform
Primary Policy Change: Establish federal public benefit corporation with authority to manufacture generic drugs, biosimilars, and strategic medical countermeasures when private markets fail, using proven cost-plus pricing model.
New Requirements:
Mandatory domestic surge capacity for essential medicines.
Cost-plus pricing transparency for all federally manufactured products (manufacturing cost plus 15% margin plus $3 pharmacy dispensing fee plus $5 direct shipping fee, publicly disclosed per batch via Federal Drug Pricing Transparency Portal).
GAO Essential Goods Docket to adjudicate market failure determinations and pricing appeals.
Federal matching for state manufacturing partnerships (2:1 federal matching of qualified state investments).
API diversification requirements reducing single-source foreign dependencies by 50%.
Federal Pharmaceutical Manufacturing Corporation (FPMC) governed by 11-member Board with 5-year staggered terms, cause-only removal, mid-term GAO performance review.
Strategic reserve inventory of 6-12 months for all products manufactured.
Surge production capability: 3-5x baseline capacity within 72 hours. 12-hour activation for 50-ton push packages³.
Biosimilar development targeting 20 products with annual per-patient cost exceeding $10,000 and market penetration below 30%4.
Advanced manufacturing incorporating continuous manufacturing and Industry 4.0 technologies with real-time Process Analytical Technology monitoring.
State partnership regional hub designations (West Coast: biologics; Midwest: oral solid dosage; East Coast: sterile injectables; Southwest: emergency preparedness; South: disaster response/tropical disease).
International supplier partnerships meeting WHO prequalification standards. Onshore analytical testing for all imported APIs.
All AI/ML production decision systems subject to independent algorithmic audit prior to deployment and biennially thereafter. 20% variance across protected classes (per Title VII) triggers mandatory GAO review. Audit logs maintained 7 years.
Real-time dashboards showing shortage status, market determinations, and appeals. Annual GAO audits minimum. Audit schedules published 2 years in advance.
New Prohibitions:
Federal manufacturing entity prohibited from competing in functional markets (4+ suppliers, stable pricing).
Prohibition on federal contracts with manufacturers causing shortages through negligence.
Prohibition on price increases exceeding 100% in 24 months for essential medicines without GAO review.
Enforcement:
GAO binding orders (after agency exhaustion) against private manufacturers requiring production, imposing penalties, or compelling corrective action.
GAO recommendations to FPMC (federal agency) with 99%+ expected compliance per Court of Federal Claims bid protest model5.
GAO annual audits of all federal manufacturing operations.
Automatic market intervention triggers upon shortage declaration exceeding 180 days.
Federal contract debarment (3-10 years) for manufacturers found to have caused shortages through negligence. Civil penalties $1M-$50M per product shortage caused.
Pattern violations (3+ adjudicated violations OR settlements with factual admissions within 24 months, including subsidiaries/affiliates): enhanced penalties scaled to 0.5% annual revenue or $10M minimum.
Civil penalties up to $10M per violation for false information to GAO.
Private right of action after GAO exhaustion AND defendant non-compliance with order. Statutory damages: $500 technical violations, $1K-$5K documented harm, $10K-$25K willful violations. Class actions capped at $50M.
Statute of limitations: 4 years from discovery OR 7 years absolute cutoff.
Judicial review: U.S. Court of Appeals for D.C. Circuit under arbitrary and capricious standard6 7.
What Changes
Before: Zero federal pharmaceutical manufacturing capacity. Private manufacturers control 100% of generic production with no accountability for shortages or price exploitation. Strategic National Stockpile dependent on same suppliers causing civilian shortages. FDA monitors shortages but cannot compel production. No independent body reviews market failure or pricing disputes. 323 active shortages with median 4-year duration. 90%+ API foreign dependence with 46 essential medicines sole-sourced from China.
After: Federal public benefit corporation with five regional manufacturing facilities and surge capacity. Transparent cost-plus pricing reducing costs 80-85% on targeted products. GAO Essential Goods Docket with binding authority (after agency exhaustion) over private manufacturers and recommendations to FPMC (99%+ compliance expected)5. Strategic reserve of 6-12 months for essential medicines. 12-hour emergency deployment capability. State partnership network with federal matching. Biosimilar development program targeting 20 high-cost biologics. 50% reduction in single-source API dependencies. GAO annual audits and algorithmic oversight. Patient and manufacturer appeal rights. Private right of action after GAO exhaustion if defendant ignores order.
ROI
Costs:
| Item | 10-Year |
|---|---|
| Tier 1 facilities and operations | $2,000,000,000 |
| Tier 2 strategic stockpile | $700,000,000 |
| Tier 3 biosimilar development | $2,500,000,000 |
| Tier 4 advanced manufacturing | $500,000,000 |
| Tier 5 state partnerships | $2,000,000,000 |
| Tier 6 international programs | $750,000,000 |
| Total | $8,450,000,000 |
Savings:
| Item | Gross | Capture | Net |
|---|---|---|---|
| Medicare Part D savings | $153B-$342B | 100% | $153B-$342B |
| Patient out-of-pocket reduction | $100B-$200B | 75% | $75B-$150B |
| Shortage mitigation | $50B-$100B | 80% | $40B-$80B |
| Biosimilar savings | $84B-$210B | 90% | $76B-$189B |
| Advanced manufacturing efficiency | $90B | 100% | $90B |
| State Medicaid savings | $80B-$120B | 100% | $80B-$120B |
| Strategic stockpile efficiency | $45B-$75B | 100% | $45B-$75B |
| International program benefits | $35B-$80B | 70% | $25B-$56B |
| Total | $584B-$1,102B |
Federal Budget Impact
Direct federal savings from Medicare Part D cost reductions and strategic stockpile efficiency: $198B-$417B over 10 years.
Societal Benefits
| Benefit | Annual | NPV (3%) | NPV (7%) |
|---|---|---|---|
| Shortage elimination | $5B-$10B | $43B-$85B | $35B-$70B |
| Price competition effects | $8B-$15B | $68B-$128B | $56B-$105B |
| Emergency preparedness | $4B-$7B | $34B-$60B | $28B-$49B |
| Innovation spillovers | $3B-$5B | $26B-$43B | $21B-$35B |
| Total | $20B-$37B | $171B-$316B | $140B-$259B |
Summary
| Category | 10-Year | Notes |
|---|---|---|
| Total Investment | $8.45B | Federal manufacturing infrastructure |
| Direct Savings | $584B-$1,102B | Healthcare system cost reduction |
| Net Federal Impact | $189B-$408B | Direct federal budget savings |
| Aggregate ROI | 79:1 to 139:1 | Total benefits to costs ratio |
References
- FDA Drug Shortage Database (Q1 2024)
- GAO Report on Drug Shortages (GAO-16-595, 2016)
- HHS ASPR Strategic National Stockpile Reports (2019-2023)
- CBO Biosimilar Savings Projections (2022)
- Court of Federal Claims bid protest 99.7% Compliance Model
- Association for Accessible Medicines v. Frosh, 887 F.3d 664 (4th Cir. 2018)
- Pharmaceutical Research and Manufacturers of America v. Walsh, 538 U.S. 644 (2003)
- Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 301 et seq.)
- Drug Price Competition and Patent Term Restoration Act (Pub. L. 98-417)
- Medicare Modernization Act (Pub. L. 108-173)
- Defense Production Act (50 U.S.C. § 4501)
- Biologics Price Competition and Innovation Act (42 U.S.C. § 262(k))
Change Log
[GAO Consolidation]: Replaced standalone "Drug Market Accountability Board" with GAO Essential Goods Docket. Market failure determinations, pricing disputes, and manufacturer accountability now adjudicated by consolidated GAO oversight body serving multiple K_Public_Benefit programs. Reduces administrative overhead, eliminates duplicative infrastructure, maintains independence through GAO placement. Board members (ALJs, health economists, supply chain experts) integrated into GAO specialized panel structure.
[Framework Standards Embedded]: Private right of action: Now requires GAO exhaustion AND defendant non-compliance with order (Section 3(g)). Statute of limitations: 4 years from discovery OR 7 years absolute cutoff (Section 3(h)). Pattern violation: 3+ adjudicated violations OR settlements with factual admissions within 24 months, including affiliates (Section 3(d), Section 4). Director/Board terms: 5 years staggered, cause-only removal, mid-term review (Section 2(a)). Reporting: Real-time dashboards, annual GAO audits minimum, schedules published 2 years advance (Sections 3(a), 3(e)). Algorithmic accountability: 20% variance triggers review not automatic violation, protected classes per Title VII (Section 3(c)). Statutory damages: Tiered by harm type, actual harm required above $1K, class action cap $50M (Section 3(g)).
[Binding Authority Clarified]: GAO issues binding orders (after agency exhaustion) against private manufacturers (constitutionalnormal regulatory authority) and recommendations to FPMC (federal agency). 99.7% compliance rate expected per Court of Federal Claims bid protest model.
[Original Red Team Provisions Retained]: Tiered manufacturing program, cost-plus pricing transparency, strategic stockpile surge capacity, biosimilar development, state partnership network, international quality assurance, API diversification, evidentiary standards for negligence, D.C. Circuit judicial reviewall substantive provisions from original document preserved.
2025-12-07 - Legislative Language Removal: Merged unique provisions into Proposed Reform section. Deleted Legislative Language section.
2025-12-07 - Inline Citations: Added superscript citations. Standardized References section.
2025-12-07 - Template Standardization: Converted ROI section to table format. Broke semicolon chains into separate sentences. Applied consistent spacing between bullet points. Removed speculative language and timelines.